國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Introduction to biologic and biosimi...

Nagel, Karen M.

Introduction to biologic and biosimilar product development and analysis

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Introduction to biologic and biosimilar product development and analysisby Karen M. Nagel.
作者:	Nagel, Karen M.
出版者:	Cham :Springer International Publishing :2018.
面頁冊數:	xi, 109 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Drug development.
電子資源:	https://doi.org/10.1007/978-3-319-98428-5
ISBN:	9783319984285$q(electronic bk.)

Introduction to biologic and biosimilar product development and analysis
Nagel, Karen M.

Introduction to biologic and biosimilar product development and analysis[electronic resource] /by Karen M. Nagel. - Cham :Springer International Publishing :2018. - xi, 109 p. :ill., digital ;24 cm. - AAPS introductions in the pharmaceutical sciences,2522-834X. - AAPS introductions in the pharmaceutical sciences..

Recombinant DNA Technology -- Therapeutic Proteins -- Therapeutic Antibodies -- Analysis and Regulation of Biologics including Biosimilars.

The purpose of this book is to give a concise introduction to development and analysis of pharmaceutical biologics for those in the pharmaceutical industry who are switching focus from small molecules to biologics processing, analysis, and delivery. In order to maintain a limited focus, Introduction to Biologic and Biosimilar Product Development and Analysis, will deal only with peptides, proteins and monoclonal antibodies.

ISBN: 9783319984285$q(electronic bk.)

Standard No.: 10.1007/978-3-319-98428-5doiSubjects--Topical Terms:

190608
Drug development.

LC Class. No.: RM301.25 / .N344 2018

Dewey Class. No.: 615.19

Introduction to biologic and biosimilar product development and analysis
LDR:01638nmm a2200337 a 4500 001 544416
003 DE-He213
005 20190307165500.0
006 m d
007 cr nn 008maaau
008 190508s2018 gw s 0 eng d
020 $a 9783319984285$q(electronic bk.)
020 $a 9783319984278$q(paper)
024 7 $a 10.1007/978-3-319-98428-5 $2 doi
035 $a 978-3-319-98428-5
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.25 $b .N344 2018
072 7 $a TDCW $2 bicssc
072 7 $a MED072000 $2 bisacsh
072 7 $a TDC $2 thema
082 0 4 $a 615.19 $2 23
090 $a RM301.25 $b .N147 2018
100 1 $a Nagel, Karen M. $3 822950
245 1 0 $a Introduction to biologic and biosimilar product development and analysis $h [electronic resource] / $c by Karen M. Nagel.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a xi, 109 p. : $b ill., digital ; $c 24 cm.
490 1 $a AAPS introductions in the pharmaceutical sciences, $x 2522-834X
505 0 $a Recombinant DNA Technology -- Therapeutic Proteins -- Therapeutic Antibodies -- Analysis and Regulation of Biologics including Biosimilars.
520 $a The purpose of this book is to give a concise introduction to development and analysis of pharmaceutical biologics for those in the pharmaceutical industry who are switching focus from small molecules to biologics processing, analysis, and delivery. In order to maintain a limited focus, Introduction to Biologic and Biosimilar Product Development and Analysis, will deal only with peptides, proteins and monoclonal antibodies.
650 0 $a Drug development. $3 190608
650 0 $a Biologicals. $3 667671
650 1 4 $a Pharmaceutical Sciences/Technology. $3 338426
650 2 4 $a Pharmacy. $3 218145
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a AAPS introductions in the pharmaceutical sciences. $3 821817
856 4 0 $u https://doi.org/10.1007/978-3-319-98428-5
950 $a Biomedical and Life Sciences (Springer-11642)